PharmacyCodes



Ramiprilum [Latin] en es it fr

Categoria

Ramiprilum [Latin] Marchi, Ramiprilum [Latin] Analoghi

Ramiprilum [Latin] Marchi miscela

  • No information avaliable

    • Ramiprilum [Latin] Formula chimica

    C23H32N2O5

    Ramiprilum [Latin] RX link

    http://www.rxlist.com/cgi/generic/ramipril.htm

    Ramiprilum [Latin] FDA foglio

    Ramiprilum [Latin] DMS (foglio di materiale di sicurezza)

    Ramiprilum_[Latin] MSDS

    Ramiprilum [Latin] Sintesi di riferimento

    EH Gold et al. US Pat. 4.587.258 (1967).

    Ramiprilum [Latin] Peso molecolare

    416.511 g/mol

    Ramiprilum [Latin] Temperatura di fusione

    109 oC

    Ramiprilum [Latin] H2O Solubilita

    3,5 mg / L

    Ramiprilum [Latin] Stato

    Solid

    Ramiprilum [Latin] LogP

    3.149

    Ramiprilum [Latin] Forme di dosaggio

    Capsula

    Ramiprilum [Latin] Indicazione

    Per i diuretici e digitale nello scompenso cardiaco congestizio come terapia aggiuntiva e per l'uso in profilassi in post infarto miocardico.

    Ramiprilum [Latin] Farmacologia

    Ramipril è un enzima di conversione dell'angiotensina (ACE) simile a benazepril, fosinopril, e quinapril. Un profarmaco inattivo, ramipril a ramiprilato viene convertito nel fegato ed è usata per trattare ipertensione e insufficienza cardiaca, di ridurre la proteinuria e la malattia renale in pazienti affetti da nefropatie, e per prevenire l'ictus, infarto miocardico e morte cardiaca nei pazienti ad alto rischio.

    Ramiprilum [Latin] Assorbimento

    Il grado di assorbimento è almeno del 50-60% e non è significativamente influenzato dalla presenza di cibo nel tratto GI, anche se il tasso di assorbimento si riduce.

    Ramiprilum [Latin] Tossicita

    Le più probabili manifestazioni cliniche sarebbero sintomi attribuibili ad ipotensione. LD50 = 10933 mg / kg (per via orale nei topi).

    Ramiprilum [Latin] Informazioni paziente

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    Angioedema: Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors, especially following the first dose. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

    Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported. Patients should be told that if syncope occurs, ramipril should be discontinued until the physician has been consulted.

    All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

    Neutropenia: Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

    Ramiprilum [Latin] Atto interessato organismi

    Gli esseri umani e altri mammiferi